We are live on ! Find out more
CANY

Caxton Associates (New York) Portfolio holdings

AUM $3.18B
1-Year Est. Return 54.49%
This Fund
S&P 500
This Quarter Est. Return
-18.82%
1 Year Est. Return
+54.49%
3 Year Est. Return
+73.91%
5 Year Est. Return
+212.89%
10 Year Est. Return
+632.2%
AUM
$1.03B
AUM Growth
-$200M
Cap. Flow
+$16M
Cap. Flow %
1.55%
Top 10 Hldgs %
58.26%
Holding
811
New
317
Increased
98
Reduced
90
Closed
269

Top Buys

Rank Stock Value
1
VAL icon
Valaris
VAL
+$24.3M
2
MRNA icon
Moderna
MRNA
+$9.63M
3
SLV icon
iShares Silver Trust
SLV
+$9.23M
4
TMUS icon
T-Mobile US
TMUS
+$9.02M
5
NE icon
Noble Corp
NE
+$6.74M

Top Sells

Rank Stock Value
1
TSLA icon
Tesla
TSLA
+$107M
2
IWM icon
iShares Russell 2000 ETF
IWM
+$29M
3
APTV icon
Aptiv
APTV
+$22.6M
4
MSFT icon
Microsoft
MSFT
+$20.8M
5
AMZN icon
Amazon
AMZN
+$12.7M

Sector Composition

Rank Sector Weight
1 Healthcare 23.31%
2 Consumer Discretionary 12.31%
3 Materials 12.15%
4 Industrials 5.19%
5 Financials 4.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESPR
501
DELISTED
Esperion Therapeutics
ESPR
$126K 0.01%
+19,768
New +$112K
TCRT icon
502
Alaunos Therapeutics
TCRT
$4.86M
$125K 0.01%
671
-271
-29% -$25.9K
GOTU icon
503
Gaotu Techedu
GOTU
$436M
$123K 0.01%
62,520
+18,863
+43% +$30.3K
VRM icon
504
Vroom Inc
VRM
$48.2M
$123K 0.01%
+1,232
New +$155K
CMRX
505
DELISTED
Chimerix, Inc.
CMRX
$123K 0.01%
+58,898
New +$189K
HLX icon
506
Helix Energy Solutions
HLX
$1.41B
$122K 0.01%
39,260
– –
TAL icon
507
TAL Education Group
TAL
$6.87B
$116K 0.01%
+23,776
New +$90.9K
ALTO icon
508
Alto Ingredients
ALTO
$340M
$112K 0.01%
+30,222
New +$158K
VLY icon
509
Valley National Bancorp
VLY
$8.04B
$112K 0.01%
+10,743
New +$128K
GTHX
510
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$106K 0.01%
+21,388
New +$118K
LILAK icon
511
Liberty Latin America Class C
LILAK
$1.64B
$104K 0.01%
+14,661
New +$122K
RWT
512
Redwood Trust
RWT
$594M
$104K 0.01%
+13,519
New +$124K
ENPC
513
DELISTED
Executive Network Partnering Corporation
ENPC
$100K 0.01%
+10,000
New +$99.4K
ATRA icon
514
Atara Biotherapeutics
ATRA
$76.1M
$97K 0.01%
+498
New +$81.3K
CHRS icon
515
Coherus Oncology
CHRS
$196M
$93K 0.01%
+12,892
New +$112K
AMSC icon
516
American Superconductor
AMSC
$1.59B
$92K 0.01%
17,832
– –
VNET
517
VNET Group
VNET
$2.09B
$92K 0.01%
+15,181
New +$89.9K
API
518
Agora
API
$377M
$89K 0.01%
+13,520
New +$95.7K
IMMR icon
519
Immersion
IMMR
$252M
$87K 0.01%
16,302
– –
SPPI
520
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$84K 0.01%
107,135
– –
YSG
521
Yatsen Holding
YSG
$319M
$83K 0.01%
+10,660
New +$36.2K
NLY icon
522
Annaly Capital Management
NLY
$17.4B
$80K 0.01%
+3,401
New +$88.1K
KC
523
Kingsoft Cloud Holdings
KC
$3.69B
$77K 0.01%
+17,298
New +$74K
CNTY icon
524
Century Casinos
CNTY
$34M
$76K 0.01%
10,535
-13,144
-56% -$123K
MRAM icon
525
Everspin Technologies
MRAM
$405M
$74K 0.01%
14,211
-10,892
-43% -$70.1K
19 20
21
22 23

Similar funds

BFM
Boston Financial Management Boston, Massachusetts $3.31B AUM 19.4% 1-Year Est. Return
MWM
Merriman Wealth Management Seattle, Washington $2.4B AUM 13.66% 1-Year Est. Return
CCM
Carlson Capital Management Northfield, Minnesota $2.29B AUM 7.48% 1-Year Est. Return
ECG
Edge Capital Group Atlanta, Georgia $2.24B AUM 19.7% 1-Year Est. Return
LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
KL
KGH Ltd Nassau, Bahamas $1.92B AUM 13.96% 1-Year Est. Return
WP
WMS Partners Towson, Maryland $1.78B AUM 11.82% 1-Year Est. Return
RDIA
RE Dickinson Investment Advisors Council Bluffs, Iowa $1.77B AUM 15.45% 1-Year Est. Return

Caxton Associates (New York)'s Q2 2022 Portfolio in Review

As of Q2 2022, Caxton Associates (New York) held 811 positions worth $1.03B, down 16% from $1.23B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Caxton Associates (New York)'s Q2 2022 filing shows 317 new, 98 increased, 90 reduced and 269 closed positions. Its largest new stake was Valaris: 451,426 shares worth $19.1M. The largest sale was Tesla, an estimated $107M.

By sector, the portfolio is most concentrated in Healthcare at 23% of assets, up from 17% a quarter earlier, followed by Consumer Discretionary and Materials.

  • Caxton Associates (New York)'s largest Q2 2022 buy was Valaris: 451,426 shares worth $19.1M.
  • Caxton Associates (New York) added most to Moderna in Q2 2022, an estimated $9.63M increase.
  • Caxton Associates (New York)'s biggest Q2 2022 reduction was Aptiv, cutting an estimated $22.6M.
  • Caxton Associates (New York) fully exited Tesla in Q2 2022, selling an estimated $107M.
  • Caxton Associates (New York)'s ten largest holdings make up 58% of its $1.03B portfolio in Q2 2022.
  • Caxton Associates (New York) opened 317 new positions and closed 269 in Q2 2022.
  • Caxton Associates (New York)'s portfolio value fell 16% quarter-over-quarter to $1.03B.

Based on Caxton Associates (New York)'s 13F filing for Q2 2022, filed 15 Aug 2022.